ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
https://launchlinks.com/jacemembers
.png)
7200 Powers Ave. #151 Jacksonville, Florida 32217
19047291091
jtparish02@outlook.com
Copyright © 2023 jacenews24. All Rights Reserved
